Beam Therapeutics (BEAM) Share-based Compensation (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Share-based Compensation data on file, last reported at $19.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $19.0 million, down 28.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.6 million (down 26.64% YoY), and the FY2025 annual result was $94.2 million, down 21.89% from the prior year.
• Share-based Compensation eased to $19.0 million in Q1 2026 per BEAM's latest filing, from $20.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $31.6 million in Q2 2024 and troughed at $18.0 million in Q1 2022.
• A 5-year average of $24.5 million and a median of $23.9 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 288.02% in 2022, then plunged 32.33% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $22.5 million in 2022, then climbed by 0.52% to $22.6 million in 2023, then soared by 33.61% to $30.2 million in 2024, then sank by 32.33% to $20.4 million in 2025, then fell by 6.87% to $19.0 million in 2026.
• Business Quant data shows BEAM's Share-based Compensation at $19.0 million in Q1 2026, $20.4 million in Q4 2025, and $22.7 million in Q3 2025.